Johnson & Johnson
$799M 13F equity value
17 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Johnson & Johnson covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| PTGX | PROTAGONIST THERAPEUTICS INC | 2,449,183 | $300M | 37.6% |
| NBTX | NANOBIOTIX | 5,623,816 | $212M | 26.5% |
| MGTX | MEIRAGTX HLDGS PLC | 6,641,064 | $90M | 11.2% |
| RAPP | RAPPORT THERAPEUTICS INC | 1,784,517 | $74M | 9.3% |
| CTNM | CONTINEUM THERAPEUTICS INC | 1,979,173 | $32M | 4.1% |
| LEGN | LEGEND BIOTECH CORP | 814,586 | $24M | 2.9% |
| CVRX | CVRX INC | 4,024,861 | $21M | 2.6% |
| XNCR | XENCOR INC | 748,062 | $12M | 1.5% |
| CBRS | CEREBRAS SYSTEMS INC | 53,586 | $12M | 1.5% |
| FATE | FATE THERAPEUTICS INC | 3,379,064 | $9M | 1.1% |
Track Johnson & Johnson's 13F portfolio: $799M in reported holdings, 17 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}